Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.

MLA

Castle, John, et al. “Rivaroxaban Compared to No Treatment in ER-Negative Stage I-III Early Breast Cancer Patients (the TIP Trial): Study Protocol for a Phase II Preoperative Window-of-Opportunity Study Design Randomised Controlled Trial.” Trials, vol. 21, no. 1, Aug. 2020, p. 749. EBSCOhost, https://doi.org/10.1186/s13063-020-04675-7.

APA

Castle, J., Blower, E., Bundred, N. J., Harvey, J. R., Thachil, J., Marshall, A., Cox, K., Cicconi, S., Holcombe, C., Palmieri, C., & Kirwan, C. C. (2020). Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial. Trials, 21(1), 749. https://doi.org/10.1186/s13063-020-04675-7

Chicago

Castle, John, Emma Blower, Nigel J Bundred, James R Harvey, Jecko Thachil, Andrea Marshall, Karina Cox, et al. 2020. “Rivaroxaban Compared to No Treatment in ER-Negative Stage I-III Early Breast Cancer Patients (the TIP Trial): Study Protocol for a Phase II Preoperative Window-of-Opportunity Study Design Randomised Controlled Trial.” Trials 21 (1): 749. doi:10.1186/s13063-020-04675-7.